Abstract
Peptic Ulcer Disease (PUD) is a prominent global gastrointestinal illness despite advancements in acid-suppressive therapy and Helicobacter pylori removal methods. Antibiotics, proton pump inhibitors, and H₂ receptor antagonists are examples of traditional anti ulcer treatments that are often limited by systemic adverse effects, drug resistance, low mucosal penetration, rapid metabolism, and poor bioavailability. In recent years, nanotechnology-based drug delivery techniques have emerged as a practical answer to these issues. One kind of nanocarrier that has attracted a lot of attention is chitosan nanoparticles (CS-NPs), which exhibit a positive surface charge, mucoadhesive qualities, biocompatibility, and biodegradability. This presentation covers in depth the pathophysiology of peptic ulcer disease, the limitations of conventional treatments, and the emerging role of nanotechnology in anti-ulcer drug delivery. Highlighted are the mechanisms of action of chitosan-based nanoparticles, including enhanced mucosal adherence, controlled and extended drug release, targeted delivery to H. pylori, and reduced systemic toxicity and stomach irritation. Recent formulation methods, preclinical data, and emerging nanocomposite systems containing phytochemicals, bioactive lipids, and antibiotics are thoroughly examined. The review also addresses CS-NP-related safety, toxicity, production challenges, stability issues, and regulatory concerns. Furthermore, recent advances in AI-powered nanomedicine and customised drug delivery are explored as possible directions for future formulation design and clinical translation. All things considered, chitosan nanoparticles are an intriguing and adaptable nanoplatform that has the potential to significantly improve anti-ulcer therapy's efficacy, safety, and patient compliance. More interdisciplinary research and carefully thought-out clinical studies are required to advance these nanosystems from preclinical success to clinical application.